A New Federal Eye on Health AI

The FTC launched a permanent Healthcare Task Force on March 20, signaling coordinated federal scrutiny of health AI, pricing, and competition

26 Mar 2026

The US Federal Trade Commission has raised the enforcement stakes for health AI. On March 20, Chairman Andrew Ferguson launched a permanent Healthcare Task Force, pulling together the agency's competition, consumer protection, economics, policy, and technology teams into a single body with one focus: healthcare.

It is a structural shift, not just a policy signal. By embedding its Office of Technology inside a dedicated healthcare enforcement unit, the FTC has placed AI-enabled clinical tools, diagnostic software, and digital health applications firmly within its enforcement crosshairs. Teams that previously operated on separate tracks will now share intelligence, align on investigations, and surface emerging issues together. The task force meets monthly and reports directly to Ferguson each quarter.

In his directive memo, Ferguson pointed to consolidation and anticompetitive conduct as the forces driving higher prices, reduced access, and stunted innovation across US healthcare. Rural communities, seniors, and veterans were named as the populations absorbing the sharpest costs. The task force is framed as a direct answer to President Trump's executive order demanding a more competitive and affordable healthcare system.

For health AI developers, the exposure runs wider than antitrust. The FTC holds broad authority under the FTC Act to pursue unfair or deceptive practices, and that mandate covers AI-generated health claims, algorithmic pricing, and data handling. The new structure gives the agency the infrastructure to deploy that authority with more coordination and aggression than any previous enforcement arrangement allowed.

The task force's reach is also set to grow. Plans to bring in the Department of Health and Human Services and the Department of Justice would add regulatory muscle, healthcare data access, and criminal enforcement tools the FTC cannot wield alone. Health AI companies could find themselves facing federal scrutiny from multiple directions at once.

Recent enforcement actions offer a preview of the task force's ambitions. A settlement with Express Scripts is projected to cut patient drug costs by up to 7 billion dollars over a decade. A medical device acquisition was blocked earlier this year. The task force is built to make outcomes like those the baseline, not the exception.

For digital health investors, AI developers, and health systems, the March 20 announcement carries a clear message: coordinated federal oversight of health AI is not coming. It is already here.